CLL cells, which expressed low levels of BCMA could be efficiently targeted by teclistamab, providing proof of principle that BCMA-directed therapies might be beneficial for other B-cell malignancy patients besides multiple myeloma. Here, TNFRSF17 is linked to plasma cell myeloma.